Dr. Wirth will lead the first human clinical study for acute spinal cord injury patients using the company’s proprietary scaffold without drugs or cells. The study is currently awaiting FDA approval and the company hopes it will begin in early 2012.
Dr. Wirth was previously the medical director for regenerative medicine with Geron, where he led the world’s first human embryonic stem cell clinical trial. He has spent the past 20 years studying the role cell therapies may play in helping patients with SCI.
Related Articles on Spine Surgery:
Humanitarian Spine Care: 5 Things to Know About Spine Africa Project
How Are Spine Surgeons Using BMP Today? 10 Surgeon Responses
A New Hope for Treating Spinal Cord Injury: 5 Points on InVivo Therapeutics’ Technology
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
